United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

by · The Cerbat Gem

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 64.4% during the third quarter, Holdings Channel reports. The institutional investor owned 32,092 shares of the biotechnology company’s stock after acquiring an additional 12,566 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in United Therapeutics were worth $11,500,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in UTHR. ClariVest Asset Management LLC raised its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth $30,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at $33,000. USA Financial Formulas bought a new position in United Therapeutics during the third quarter valued at about $33,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics during the third quarter worth about $82,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

UTHR stock opened at $372.89 on Friday. The stock has a market cap of $16.65 billion, a P/E ratio of 16.38, a P/E/G ratio of 1.07 and a beta of 0.56. The firm has a 50 day simple moving average of $365.06 and a 200 day simple moving average of $331.82. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same period in the previous year, the company posted $5.38 EPS. United Therapeutics’s revenue was up 22.9% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on UTHR shares. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Jefferies Financial Group upped their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. Finally, TD Cowen upped their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

Read Our Latest Stock Report on UTHR

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 269 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. This trade represents a 67.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 7,802 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. The trade was a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 117,496 shares of company stock valued at $43,765,042 in the last three months. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Free Report).